Charles River Laboratories International, Inc. (CRL) Stock Price & Analysis
Charles River Laboratories International, Inc. (CRL) — MoonshotScore 70/100 (Strong band), calculated Nov 18, 2026. Price $314.32 (-4.15%), as of the Nov 20, 2026 trading session; market cap $15.1B. Expected results Feb 17, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Charles River Laboratories International, Inc. · CRL · NYSE · Healthcare · Medical Diagnostics & Research
Research dated 2026-09-13: Charles River Laboratories supplies pharmaceutical and biotechnology companies with research models, outsourced discovery and safety work, manufacturing quality testing, and managed animal facilities rather than developing its own drug portfolio. The case depends on whether recovering demand in Discovery and Safety Assessment and a more profitable Manufacturing mix can outweigh divestiture-related revenue contraction and a heavy debt burden.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Charles River Laboratories International (CRL)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $1.00B (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- expected results Feb 17, 2027
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 68 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 70 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $314.32 | |
| Change on the day | -4.15% | |
| 52-week range | $146.20–$379.63 | |
| Market capitalisation | $15.1B | — |
| Price / earnings (trailing) | 325.65 | |
| Shares traded on the day | 1.15M | |
| Beta (volatility vs the S&P 500) | 1.34 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Charles River Laboratories International (CRL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Charles River Laboratories International (CRL), and what does it report?
Short answer · as of
Research Models and Services provides laboratory animals, engineered models, diagnostics, and facility support.
Research dated 2026-09-13.
Discovery and Safety Assessment advances client compounds and biologics through target validation, toxicology, pathology, pharmacology, bioanalysis, metabolism, and pharmacokinetic work, while Manufacturing Solutions provides quality-control testing, biologics testing, and specialized vaccine-production inputs.
Discovery and Safety Assessment contributes most of the segment revenue, so the consolidated figures chiefly reflect client spending on preclinical programs. Revenue measures outsourced research activity, model demand, facility services, and testing volumes—not sales from medicines owned by Charles River.
What do the latest results show for Charles River Laboratories International (CRL)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1.00B.
Research dated 2026-09-13.
Revenue edged higher from the immediately preceding period but remained below the comparable prior period. Gross profit recovered, operating profit was essentially unchanged, and the statutory net loss narrowed sharply.
Revenue and the earnings measure used for estimate comparisons have exceeded expectations throughout the displayed earnings history, although recent statutory results have included losses. Management attributes the expected reported revenue contraction primarily to completed divestitures and says underlying growth should benefit from improving Discovery and Safety Assessment demand and a rebound in Biologics Testing; it also expects the CDMO divestiture to improve Manufacturing margins while higher performance-based compensation raises corporate costs.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1.00B | $54M | $1.10 (diluted) |
| Q4 FY2025 | $994M | -$277M | -$5.62 (diluted) |
| Q1 FY2026 | $996M | -$15M | -$0.30 (diluted) |
| Q2 FY2026 | $1.00B | -$1M | -$0.03 (diluted) |
What are the financial strengths and risks for Charles River Laboratories International (CRL)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow remained positive throughout the displayed period and strengthened most recently, while lower capital spending improved the cash left after investment in the business. Cash and short-term investments moved only modestly across the reported window, and long-term investments provide an additional balance beyond that immediately available pool.
Even after including those investments, the balance is far below total debt. Working-capital ratios sit above parity, but leverage is meaningful and trailing net returns are negative; renewed weakness in client preclinical spending would pressure the dominant Discovery and Safety Assessment segment while leaving less financial flexibility.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 325.65 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Charles River Laboratories International (CRL)?
Short answer · as of
The next earnings report is expected on Feb 17, 2027.
Research dated 2026-09-13.
At the scheduled earnings release, watch the split between divestiture-driven reported contraction and underlying activity. Improving Discovery and Safety Assessment demand, faster Biologics Testing growth, and a richer Manufacturing margin would support management’s account; broader weakness or rising corporate costs that absorb those benefits would challenge it.
Consensus expectations embed near-term revenue below the latest annual result followed by expansion in later forecast periods. Cash conversion therefore matters alongside earnings comparisons: continued operating cash generation would help contain balance-sheet risk, while deterioration would make the debt load more consequential.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Charles River Laboratories International compare with its peers?
Short answer
Charles River Laboratories International's score ranks 5th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Charles River is not primarily a patient-diagnostics company. It sells research inputs and outsourced scientific work used during drug discovery, non-clinical development, safety evaluation, and manufacturing quality control.
Its unusual breadth runs from breeding research models and operating client vivariums to evaluating drug candidates and testing biologics. A CRO concentrated on study execution lacks that same connection to laboratory inputs and managed facilities, yet Charles River’s revenue concentration still makes preclinical development demand the dominant economic exposure.
| Company | Price | Market value | Score |
|---|---|---|---|
| $319.12 Nov 20, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $49.30 Nov 20, 2026 | $10.2B | 83 5-pillar Nov 18, 2026 | |
| $161.03 Nov 20, 2026 | $10.1B | 76 5-pillar Nov 18, 2026 | |
| $145.22 Nov 20, 2026 | $16.2B | 71 5-pillar Nov 18, 2026 | |
| Charles River Laboratories International (CRL) — this page | $314.32 | $15.1B | 70 |
| $25.39 Nov 20, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $219.00 – $388.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $313.67
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $330.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 96
- Identified insiders
- 10
- Purchases
- 1
- Sales
- 21
- Other transactions
- 74
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CRL in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.09% | $20.81M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Charles River Laboratories International (CRL)?
Charles River Laboratories International Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Charles River’s Discovery and Safety Assessment segment actually sell?
It sells outsourced work that helps clients identify and validate therapeutic targets, evaluate compounds and antibodies, and prepare candidates for safety assessment through toxicology, pathology, pharmacology, bioanalysis, metabolism, and pharmacokinetic services.
Why can the CDMO divestiture shrink Charles River’s revenue while lifting Manufacturing Solutions margins?
Removing the divested operation reduces reported revenue, while management expects the remaining Manufacturing mix to carry stronger margins once the divestiture effect is fully reflected. The improvement still has to overcome higher expected corporate costs.
How do Charles River’s research models and contract vivariums reinforce each other?
Charles River supplies laboratory animals and related diagnostics while also managing animal housing, care, and research facilities for biopharmaceutical clients. That places it inside both the research input purchase and the ongoing operation of the client’s preclinical environment.
Why can Charles River beat earnings estimates while reporting a statutory loss?
The estimate-comparison earnings series and income-statement diluted earnings are different presentations. The latest comparison shows an earnings beat while the statutory line remained slightly negative, so an estimate beat does not by itself establish positive net income.
What is the CRL stock price today?
The last price recorded for Charles River Laboratories International, Inc. (CRL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CRL price target?
The last analyst consensus price target we captured for Charles River Laboratories International, Inc. (CRL), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com